共 50 条
- [21] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)BLOOD, 2022, 140 : 3728 - 3730Maakaron, JosephAsch, Adam S.Popplewell, Leslie L.Collins, Graham P.Flinn, Ian W.Ghosh, NilanjanKeane, ColinKu, MatthewMehta, AmitkumarRoschewski, MarkO'Hear, CarolRen, XuehanVilla, BerthaLal, InduSmith, Sonali M.Advani, Ranjana H.
- [22] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249Kalakonda, NageshCavallo, FedericaFollows, GeorgeGoy, AndreVermaat, Joost S. P.Casasnovas, OlivierLavee, OrlyMaerevoet, MarieZijlstra, JoseeBakhshi, SameerBouabdallah, RedaChoquet, SylvainGurion, RonitHill, BrianJaeger, UlrichSancho, Juan-ManuelSchuster, MichaelThieblemont, CatherineDe la Cruz, FatimaEgyed, MiklosMishra, SouravOffner, FritzVassilakopoulos, TheodorosWarzocha, KrzysztofMcCarthy, DanielMa, XiwenCorona, KellySaint-Martin, Jean-RichardJoshi, AnitaShah, JatinVan den Neste, EricCanales, Miguel
- [23] Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyREVISTA CHILENA DE LITERATURA, 2024, (109): : 1184 - 1193Caimi, Paolo F.Ai, Weiyun Z.Alderuccio, Juan PabloArdeshna, Kirit M.Hamadani, MehdiHess, BrianKahl, Brad S.Radford, JohnSolh, MelhemStathis, AnastasiosZinzani, Pier LuigiWang, YingQin, YajuanWang, LuqiangXu, Zhiying CindyCarlo-Stella, Carmelo
- [24] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68Bell, Jill A.Cherepanov, DashaRevicki, DennisSpeck, Rebecca M.Swett, LauraStumpo, KateRong, YuanxinGordon, Leo I.
- [25] CHARACTERIZATION AND MANAGEMENT OF CUTANEOUS REACTIONS IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH LONCASTUXIMAB TESIRINE IN THE LOTIS-2 TRIALONCOLOGY NURSING FORUM, 2022, 49 (02) : E59 - E59Pruett, JulieZellner, KatieKahl, BradUngar, DavidWang, LuqiangHamadani, Mehdi
- [26] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377Vukcevic, MirkoYung, MalloryKhan, MaliHoupt, BethanySchnell, Frederick
- [27] The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)BLOOD, 2018, 132Lenz, GeorgRutherford, Sarah C.Davies, AndrewZinzani, Pier LuigiSalles, GillesHasskarl, JensMargunato-Debay, SandraRodrigues, FilipeNientker, LisetteBalradj, JanitaAlleman, Cathelijne
- [28] Patient, caregiver, and physician preferences for treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18710 - E18710Vukcevic, MirkoYung, MalloryKhan, MalihaSchnell, Frederick Mark
- [29] Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspectiveCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 474 - 482Moertl, BernhardDreyling, MartinSchmidtl, ChristianHoster, EvaSchoel, WolfgangV. Bergwelt-Baildon, MichaelBerger, Karin
- [30] Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphomaBLOOD ADVANCES, 2022, 6 (16) : 4816 - 4820Jaeger, UlrichTam, Constantine S.Borchmann, PeterMcGuirk, Joseph P.Johansen, MarianneWaller, Edmund K.Jaglowski, SamanthaAndreadis, CharalambosFoley, Stephen R.Westin, Jason R.Fleury, IsabelleHo, P. JoyMielke, StephanTeshima, TakanoriSalles, GillesSchuster, Stephen J.He, FionaMaziarz, Richard T.Mayer, SebastianMakita, ShinichiKersten, Marie J.Ghosh, MonalisaWagner-Johnston, NinaKato, KojiCorradini, PaoloGoto, HidekiColicino, SilviaAgarwal, AbhijitLobetti-Bodoni, ChiaraBishop, Michael R.